ライフサイエンスコーパス: prostaglandin D

1 polipoprotein E, protein phosphatase 2A, and prostaglandin D.

2 ve agonist of the DP(2) receptor, 15R-methyl prostaglandin D(2) (15R-D(2)).

3 tamine, cysteinyl-leukotrienes (cys-LTs) and prostaglandin D(2) (PGD(2) ) was assessed as was express

4 Here, we show that increases in prostaglandin D(2) (PGD(2)) expression in mouse lungs up

5 hat mediates the pro-inflammatory effects of prostaglandin D(2) (PGD(2)) generated in allergic inflam

6 or upregulating COX-2 expression and causing prostaglandin D(2) (PGD(2)) generation.

7 lt of increased levels of the lipid mediator prostaglandin D(2) (PGD(2)) in the respiratory tract wit

8 Prostaglandin D(2) (PGD(2)) is a cyclooxygenase (COX) pr

9 Prostaglandin D(2) (PGD(2)) is known to have antipruriti

10 omologous molecule on Th2 cells (CRTH2) is a prostaglandin D(2) (PGD(2)) receptor, expressed by Th2 c

11 o mediate the metabolism of sex hormones and prostaglandin D(2) (PGD(2)), a lipid mediator that promo

12 pressed on TH2 cells (CRTH2), a receptor for prostaglandin D(2) (PGD(2)), is expressed by human ILC2s

13 nism, thought to be caused by the release of prostaglandin D(2) (PGD(2)), is not well understood.

14 Prostaglandin D(2) (PGD(2)), mainly produced by mast cel

15 e effect of inhaled PGE(2) on the release of prostaglandin D(2) (PGD(2)), preformed mast cell mediato

16 racerebroventricular (icv) administration of prostaglandin D(2) (PGD(2); 20 microg/5 microl) to consc

17 es, eosinophils and basophils in response to prostaglandin D(2) and may be involved in the pathogenes

18 In the developing testis, prostaglandin D(2) may act as a paracrine factor to indu

19 thesis was developed for the production of a prostaglandin D(2) receptor antagonist for the treatment

20 for the production of the core structure of prostaglandin D(2) receptor antagonists for the treatmen

21 tment of bone marrow-derived mast cells with prostaglandin D(2) reduced their ability to generate leu

22 ed by CD34(+) cells, decreased apoptosis and prostaglandin D(2) release by cultured MCs, and higher p

23 cts of gene knock-out (KO) of lipocalin-type prostaglandin D(2) synthase (L-PGDS), a protein found at

24 Most striking is lipocalin prostaglandin D(2) synthase (L-PGDS), which catalyzes th

25 transcript 6), and a prostaglandin synthase (prostaglandin D(2) synthase).

26 J(2)) are naturally occurring derivatives of prostaglandin D(2) that have been suggested to exert ant

27 Bronchoalveolar lavage (BAL) fluid prostaglandin D(2)(PGD(2)) levels are increased in patie

28 d an increased anti-inflammatory derivative (prostaglandin D(2)).

29 ew blockers of specific mediators, including prostaglandin D(2), IL-5, IL-9, and IL-13, are also in c

30 Exocytosis and the generation of prostaglandin D(2), LTB(4), and 5-hydroxyeicosatetraenoi

31 ls, eosinophils and basophils in response to prostaglandin D(2).

32 s masculinising environment is to synthesise prostaglandin D(2).

33 ry (LC-MS/MS) assay that accurately measures prostaglandins D(2) (PGD(2)) and E(2) (PGE(2)) in cell c

34 ts of PGD(2), prostaglandin J(2), as well as prostaglandin D receptor (DP) agonists and antagonists o

35 ing, chemokine ligand 5 (CCL5) hematopoietic prostaglandin D synthase (HPGDS) and neuropeptide S rece

36 PGD(2), which is generated by hematopoietic prostaglandin D synthase (HPGDS), acts on 3 G protein-co

37 Our results show that lipocalin-type prostaglandin D synthase (L-PGDS) and prostaglandin D2 (

38 n proinflammatory conditions, Lipocalin-type prostaglandin D synthase (L-PGDS) expression by neurons

39 e found to have elevated levels of Lipocalin prostaglandin D synthase (L-PGDS) expression in BAT and

40 is study, we define a new role for lipocalin prostaglandin D synthase (L-PGDS) in the control of meta

41 trated a twofold reduction in lipocalin-type prostaglandin D synthase (L-PGDS) transcript levels, aft

42 ed for the urinary biomarkers lipocalin-like prostaglandin D synthase (L-PGDS), alpha(1) -acid glycop

43 of decorin and significantly lower levels of prostaglandin D synthase (PGDS) and keratan sulfate.

44 cid sequencing revealed that the protein was prostaglandin D synthase (PGDS).

45 ression of prostaglandin synthase-1 (PGHS1), prostaglandin D synthase (PTGDS), human prostaglandin tr

46 Prostaglandin D synthase and tryptase transcripts were e

47 cological blockade of cyclooxygenase-2 or of prostaglandin D synthase prevented the effects of increa

48 ient substrate for the hematopoietic type of prostaglandin D synthase resulting in formation of HKD(2

49 ilar to those of GSH-dependent hematopoietic prostaglandin D synthase, except for the two large loop

50 ssociated with allergic responses, including prostaglandin D synthase, histamine receptor type 1 (H1R

51 reater IL-5 and IL-13 than did hematopoietic prostaglandin D synthase-negative and CD161(-) cT(H)2 ce

52 H)2 cells-positive (CRTH2(+)), hematopoietic prostaglandin D synthase-positive CD161(hi) CD4 T cells.